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BEGL1NGER, C., W. BORN, R. Mtd"NCH, A. KURTZ, J.-P. GUTZWILLER, K. J.~GER AND J. A. FISCHER. Distinct he- 
modynamic and gastric effects of human CGRP I and H in man. PEPTIDES 12(6) 1347-1351, 1991.--The human calcitonin 
gene-related peptides I and II (or ct and 13) (CGRP I and II) are encoded by two different genes, but they have 34 of the 37 amino 
acid residues in common. Human CGRP I more potently stimulated blood flow through the skin and carotid artery (p<0.01), and 
the heart rate (p<0.05), and plasma renin activity and aldosterone s cretion than human CGRP H (p<0.02). Inhibition of penta- 
gastrin-stimulated gastric acid output, on the other hand, was only obtained with CGRP II. The separate effects of human CGRP I 
and I1 on the cardiovascular nd gastric systems are presumably mediated by different receptors or receptor pathways recognized 
by the two closely related neuropeptides. 
Aldosterone Calcitonin gene-related peptide Gastric acid secretion Renin activity Vasodilatation 
HUMAN and rat calcitonin gene-related peptides I and II (or ct 
and 13) (CGRP I and II) differ in only 3 and 1 of the 37 amino 
acid residues, respectively (1,31). They are products of two sep- 
arate genes. In man, the two genes are located on the same 
chromosome 11 and may have arisen by gene duplication (31). 
The relative expression of human CGRP I and II at the level of 
mRNA and mature peptides varies in different issues (6, 15, 
28, 34, 35). CGRP exerts profound effects on the cardiovascu- 
lar system of man and experimental nimals, which include va- 
sodilatation, positive chronotropic and ionotropic actions on the 
heart, and stimulation of plasma renin activity (5, 9-11, 20, 32). 
The latter effect represents a counterregulatory mechanism to the 
hypotension evoked by CGRP, but CGRP also directly stimu- 
lated the release of renin from juxtaglomerular cells (20). 
CGRP, moreover, inhibits gastric acid secretion with un- 
changed mucosal blood flow (19, 22, 23, 33). We have reported 
earlier that human CGRP II, unlike CGRP I, inhibits pentagas- 
trin-stimulated acid output (3). 
To address other potentially different biological targets of 
human CGRP I and II, we have now compared the cardiovascu- 
lar effects of the two CGRPs, and have reexamined the inhibi- 
tion of gastric acid output. The results provide evidence that 
human CGRP I more potently stimulates blood flow in the skin 
and the common carotid artery, and plasma renin activity and 
aldosterone l vels than CGRP II, but does not suppress gastric 
acid secretion. 
1Requests for reprints hould be addressed toDr. J. A. Fischer, Klinik 
METHOD 
Peptides 
Synthetic human CGRP I and II (or a and 13) were purchased 
from Peninsula Laboratories (Belmont, CA). Over 95% of the 
immunoreactive material eluted as a single peak on reversed- 
phase HPLC (28). The CGRP was dissolved in 0.15 M NaC1 
containing 0.1% human serum albumin, and vials containing 6.6 
nmol/ml were prepared under aseptic conditions by the Univer- 
sity of Basel Hospital Pharmacy and were stored at - 20°C. The 
concentration of CGRP peptides obtained by weighing and by 
radioimmunoassay was within 10% of the predicted values. 
Pentagastrin (Peptavlon) was purchased from ICI Pharma 
(Lucerne, Switzerland). 
Experimental Protocols 
Six healthy men were selected for study. Their ages ranged 
from 23 to 29 years and their body weights (63 to 84 kg) were 
normal. 
Blood flow, arterial pressure, heart rate, and plasma renin 
activity and aldosterone l vels were measured before, during and 
after intravenous infusions of 79 or 263 pmol/kg/h uman CGRP 
I or II (25 ml/h for 60 min) through an indwelling catheter in a 
forearm on four different days in random order. 
Skin blood flow was studied with a laser Doppler instrument 
Balgrist, Forchstrasse 340, 8008 Zurich, Switzerland. 
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(PeriFlux PF2, Perimed, Sweden) (18). The gain selector was 
set to 30/4 kHz and the time constant to 0.2 s. The flux values 
are given in arbitrary units, which correspond to 1 V output. 
The probe head was inserted in the unheated probe holder and 
fixed to the skin 2 cm below the right clavicle, in the medio- 
clavicular line. 
Blood flow through the left common carotid artery was mea- 
sured using an ultrasonic duplex system (ND 256-8, Biosound, 
Indianapolis, IN) (18). The B-mode image of the common ca- 
rotid artery was generated with an 8 MHz transducer. Arterial 
diameters were measured from the B-mode (mean of 3 measure- 
ments). The transmitted frequency of the pulsed Doppler was 6.5 
MHz. The size of the sample was adjusted to the cross-sectional 
area of the vessel. The incident angle of the ultrasound beam 
with respect to the axis of the vessel was displayed on the 
screen. The necessary correction for calculation of absolute ve- 
locity values was automatically performed by appropriate soft- 
ware in the machine. The Doppler signals were analyzed by a 
real time spectrum analyzer (Fast Fourier Transform) providing 
200 spectra per second, with a resolution of 100 Hz. The mean 
velocity was determined from the velocity (cm/s) vs. time wave- 
forms. Blood flow was computed by multiplying the cross-sec- 
tion by the time-averaged mean velocity. 
The heart rate and the systolic and diastolic pressures were 
monitored every 15 min. 
Pentagastrin-stimulated gastric output was measured after an 
overnight fast (3). A double-lumen gastric tube was placed, un- 
der fluoroscopic guidance, into the most dependent part of the 
stomach. Polyethylene glycol 4000 was instilled into the stom- 
ach at a flow rate of 200 ml/h, and its recovery fraction was 
calculated to correct for pyloric loss. Pentagastrin (390 pmol/ 
kg/h) was infused intravenously for 190 min. Ten min after the 
start of the pentagastrin fusion, CGRP I or II (79 pmol/kg/h) 
or 0.15 M NaC1 containing 0.1% human serum albumin alone 
(control) were intravenously infused at 25 ml/h on three differ- 
ent days in random order. Gastric juice was collected in 20-min 
aliquots with continuous mechanical suction. After recording the 
volume of the aspirate, each aliquot was analyzed for titratable 
acid (autotitration with 0.01 M NaOH to an end point of pH 
7.0) and polyethylene glycol concentration (turbidimetrically). 
Radioimmunoassays 
Plasma renin activity and plasma levels of aldosterone and of 
CGRP I and II were measured by specific radioimmunoassays 
(4, 20, 28) in blood samples obtained from an indwelling cathe- 
ter placed in the contralateral forearm from the CGRP-infused 
forearm. Blood was collected into ice-chilled tubes containing 
lithium heparin as an anticoagulant and 5000 KIU aprotinin 
(Trasylol) per 5 ml of blood. Samples were immediately centri- 
fuged at 4°C and the plasma was stored at -20°C until assayed. 
All the samples from the same subject were determined in the 
same assay. 
Calculations and Statistical Analysis 
The metabolic learance rate was determined using the con- 
stant infusion to equilibrium ethod (16). 
The CGRP responses were evaluated using t-tests with Bon- 
ferroni's correction. The significance of differences between 
CGRP I and II was tested using analysis of variance followed 
by the nonparametric Friedman test. p<0.05 was considered 
statistically significant. 
RESULTS 
With 79 pmol/kg/h human CGRP I, skin mean blood flow 
was increased up to 6-fold, between 15 and 120 min after the 
start of the infusion (p<0.05), and flow through the common 
carotid artery was raised up to 1.5-fold between 15 and 60 min 
after the start of the CGRP I infusions (p<0.05) (Fig. 1). The 
raised skin blood flow responses were slightly delayed compared 
to the carotid blood flow. Statistically significant vasodilatation 
was not observed with equimolar amounts of CGRP II (p>0.05). 
Analysis of variance revealed statistically significant differences 
between the action of CGRP I and II in skin blood flow, 
F(1,13)=6.93, p<0.02, and in the common carotid artery, 
F(1,13) = 8.91, p<0.02. 
The diastolic arterial pressure was lowered with 79 pmol/kg/h 
CGRP I between 15 and 45 min after the start of the infusions 
(p<0.05), but not significantly with 79 pmol/kg/h CGRP II 
(p>0.05). The difference between the actions of 79 pmol/kg/h 
CGRP I and II was statistically significant, F(1,13) = 6.55, p<0.05. 
With 263 pmol/kg/h CGRP I and II, similar falls of the diastolic 
arterial pressure were observed between 15 and 45 min after the 
start of the infusions (p<0.05). The systolic arterial pressure re- 
mained unchanged (not shown). Statistically significant stimula- 
tion of the heart rate was obtained with 79 pmol/kg/h CGRP I 
between 30 and 60 min after the start of the infusions, and with 
263 pmol/kg/h of both CGRP I and II between 15 and 60 min 
(p<0.05). The stimulation was more pronounced with 263 pmol/ 
kg/h CGRP I than CGRP II, F(1,13)= 11.81, p<0.01. 
Moreover, 263 pmol/kg/h CGRP I stimulated plasma renin 
activity between 50 and 75 min after the start of the infusions, 
and, with a temporal delay between 40 and 105 min, plasma 
aldosterone l vels (p<0.05). Unlike 79 pmol/kg/h CGRP II, 79 
pmol/kg/h CGRP I stimulated plasma ldosterone l vels between 
60 and 75 min (p<0.05). The increase in plasma renin activity 
and aldosterone l vels was more pronounced with CGRP I than 
II, F(1,13)=9.09 and 8.92, p<0.01 and p<0.02. 
In contrast, inhibition of pentagastrin-stimulated gastric acid 
output was only recognized with 79 pmol/kg/h CGRP II between 
20 and 180 min after the start of the infusions (p<0.05), 
and not with 79 pmol/kg/h CGRP I, F(1,17)=20.12, p<0.01 
(Fig. 2). 
Plasma levels of endogenous CGRP I and II combined prior 
to the administration f the CGRP were lower than 26 pmol/1. 
As a result of the intravenous infusions of 263 pmol/kg/h uman 
CGRP I or II, plasma levels of CGRP I and II were 194±26 
pmol/l and 209---38 pmol/1, respectively. The metabolic lear- 
ance rates of CGRP I and II were 24.5 ±2.9 ml/min/kg and 
24.9 ± 5.6 ml/min/kg and were indistinguishable. 
DISCUSSION 
We have reported earlier that human CGRP II, unlike CGRP 
I, suppressed the pentagastrin-stimulated gastric acid output (3). 
Concerning the inhibition of gastric acid output by CGRP II, the 
results obtained in the present report were indistinguishable. 
Here the comparison between the effects of human CGRP I and 
II has been extended to the cardiovascular action of the neu- 
ropeptides. Enhanced blood flow in the common carotid artery, 
with a temporal delay in the skin, has been recognized as a sen- 
sitive action of human CGRP I in normal man (5,18). In con- 
trast to the inhibition of gastric acid secretion, CGRP II used at 
the same rate had no consistent effects on blood flow through 
the skin and the carotid artery. The fall of the diastolic arterial 
pressure and stimulation of the heart rate were more pronounced 
with CGRP I than with CGRP II. The differential action of the 
two CGRPs was also recognizable with the stimulation of the 
plasma renin activity. Renin activity was stimulated irectly in 
the isolated rat kidney perfused at constant pressure and in iso- 
lated rat juxtaglomerular cells (20,21). This effect is mediated 
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FIG. 1. Skin and carotid blood flow, heart rate, arterial pressure, plasma renin activity and aldosterone l vels in response to intravenous 
infusions of synthetic human CGRP I (closed symbols) or II (open symbols) in 6 healthy male subjects. CGRP I or II were infused 
between time "0" and 60 min. The 79 pmol/kg/h infusions are represented by triangles and 263 pmol/kg/h by circles. Data are mean 
values -+ SEM. 
through the protein kinase A pathway (20). But renin activity is 
also enhanced as a result of the hypotension-evoked release of 
norepinephrine and epinephrine (9-11, 20, 32). With a temporal 
delay and presumably as a consequence of the stimulation of re- 
nin activity, plasma levels of aldosterone were raised more dra- 
matically with CGRP I than with CGRP II. The stimulation of 
aldosterone secretion by CGRP in dogs in vivo and in perfused 
rat adrenal glands may be caused by the lowered arterial pres- 
sure and localized vasodilatation (14). When the heart rate and 
arterial pressure were maintained in dogs in vivo, plasma renin 
activity was raised with CGRP, but plasma aldosterone levels 
were suppressed (27). Inhibition of aldosterone secretion was 
also noted in isolated rabbit glomerulosa cells (26). Overall, the 
renin-angiotension-aldosterone system, as counterregulatory ac- 
tion to the vasodilatation and hypotension, was more potently 
activated with CGRP I than with CGRP II. 
The metabolic learance rates of CGRP I and II, as shown 
here, were indistinguishable. Differences in the metabolism of 
CGRP I and II, therefore, do not contribute to the distinct bio- 
logical effects of the two CGRPs recognized. 
The existence of receptor subtypes with different affinities for 
CGRP I and II appears, therefore, likely. Upon cross-linking, 
human CGRP 1(1-37) and -(8-37), and CGRP 11(1-37) interact 
with the same apparent molecular weight (M r 60 K, 54 K and 
17 K) binding proteins in the human cerebellum (30). On recep- 
tor autoradiography, however, subtle differences in the regional 
distribution of 125I-human CGRP I and II binding, e.g., in the 
human ventromedial hypothalamus, have been observed (13). 
The N-terminal fragments of human CGRP I(1-12), -(1-15), and 
-(1-22) lowered the arterial pressure in rats in higher amounts 
than the intact peptide (24). The more potent cardiovascular c- 
tion of CGRP I in relation to CGRP II may be influenced by the 
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FIG. 2. Pentagastrin-stimulated gastric acid output (retool/15 min) in re- 
sponse to human CGRP I or CGRP II in 6 healthy male subjects. Re- 
suits (mean___ SEM) are expressed as changes from control experiments 
with pentagastrin alone. Pentagastrin-stimulated aci  output before and 
at the end of the CGRP I infusions were: 6.2---0.4 mmol/15 min and 
6.4 -+0.5 mmol/15 min, respectively; 6.5 __-0.7 mmol/15 min and 5.2+0.5 
mmol/15 min with CGRP II; and 5.9---0.6 mmol/15 min and 6.3-+0.7 
mmol/15 min in the controls. 
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interaction of the negatively charged aspartate in position 3 of 
human CGRP I vs. the neutral asparagine in CGRP II. The 
C-terminal fragment human CGRP I(8-37), in contrast, caused 
vasoconstriction i  rats (12), and antagonized positive chrono- 
tropic and ionotropic effects on the heart (7). But the antagonis- 
tic potency of CGRP I(8-37) was much weaker on the relaxation 
of the vas deferens of the rat (7), which is consistent with re- 
ceptor heterogeneity in different target tissues (13,29). Along 
similar lines, the linear analog [acetamidomethyl-Cys2'7]human 
CGRP I retained high potency on the relaxation of the vas defe- 
rens but lost the positive chronotropic effect on the heart (8). 
We speculate that the C-terminal parts of human CGRP II are 
important for the inhibition of gastric acid output. There the 
contribution of a methionine residue in position 22 in the place 
of a valine in human CGRP I(1-37) and a serine in the place of 
an asparagine in position 25 to the amphiphilic a-helix in the 
C-terminal tail of human CGRP I remains to be assessed (25). 
A parallel stimulation of gastric blood flow by human CGRP 
I and II in rabbits concomitant with increased pentagastrin-stim- 
ulated acid output with human CGRP I and inhibition with hu- 
man CGRP II also points to differentiated regulatory functions 
of the two closely homologous neuropeptides (2). 
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